Fiscal Year 2026 Financial Results and Management Plan Briefing ― Reassessment of the Management Plan Toward FY2030 ―

Fiscal Year 2026 Financial Results Overview

Net sales for the fiscal year ending March 2026 reached 41,899 million yen (up 3.4% YoY), mainly driven by substantial growth in overseas hematuria test reagent and medical device sales. Operating profit was 2,919 million yen (down 2.7% YoY), due to changes in sales composition leading to decrease, but profit increased to 3,708 million yen (up 66.5% YoY) supported by gains from the transfer of equity interests of consolidated subsidiaries. Segment-wise, domestic and international hematuria test sales rose, as did medical devices, while microbial, instruments & food environment, and genetic-related segments decreased.

Forecast for FY2027 and Reassessment of the FY2030 Management Plan

The full-year forecast for FY2027 projects net sales of 42 billion yen (up 0.2% YoY), operating profit of 3,007 million yen (up 5.2% YoY), and net income attributable to owners of parent of 2,070 million yen (down 44.2% YoY). The company expects to achieve increase in revenue and profit, with domestic sales mainly driven by core products and overseas sales reaching 95.1% of the budget despite the closure of USAID. Additionally, the FY2030 management plan (FY2026-FY2030) will be restructured as a mid-term plan, emphasizing ROIC management, improving capital efficiency and profitability. Organizational and cultural reforms, strengthening markets and brands, and establishing systems for growth investments and M&A will be advanced.